Welcome : Guest

ALLERGY DRUGS - A US MARKET REPORT   

Research Abstract

This report analyzes the US Market for Allergy Drugs in US$ Million by the following types - Prescription Antihistamines, Prescription Corticosteroids, and OTC Allergy Drugs. Annual estimates and forecasts are provided for the period 2007 through 2015. Also, a six-year historic analysis is provided for these markets. Market data and analytics are derived from primary and secondary research. Company profiles are primarily based upon search engine sources in the public domain. The report profiles 108 companies including many key and niche players such as -

Collegium Pharmaceutical, Inc.
McNeil Consumer Healthcare
Meda Pharmaceuticals, Inc.
Novartis Consumer Healthcare, Inc.
Schering-Plough Corp.
Vicks

Click here to request a full list of companies covered in the report...

Code: MCP-6165
Price: $3950
Companies: 108
Pages: 555
Date: February 2010
Market Data Tables: 134
 



TABLE OF CONTENTS


  ALLERGY DRUGS (Complete Report) Pages : 555   | $3950

   Study Reliability and Reporting Limitations.....I-1  
   Disclaimers.....I-2
Data Interpretation & Reporting Level.....I-2
  
   Product Definitions and Scope of Study.....I-3  
   Allergy – A Global Perspective.....II-1
Allergy Prevalence.....II-1
Allergy - A US Perspective.....II-1
Allergy Prevalence.....II-1
1$105
   Market Overview.....II-2
Market Outlook.....II-2
Manufacturers Leverage Opportunity, Announce New Product Launches.....II-2
1$105
   Zyrtec’ Move to OTC Aisles Perks Up OTC Sales.....II-3
Allergy Patients Turn to Complimentary Medicine.....II-3
Leading Allergy Products.....II-3
1$105
   Table 1: US Allergy Drugs Market - Percentage Share Breakdown of Antihistamine Products by New Prescriptions for 2007, 2008 and 2009 (includes corresponding Graph/Chart).....II-41$350
   Table 2: US Allergy Drugs Market - Percentage Share Breakdown of Antihistamine + Decongestant Combination Products by New Prescription for 2007, 2008 and 2009 (includes corresponding Graph/Chart).....II-51$350
   Table 3: US Allergy Drugs Market - Percentage Share Breakdown of Allergy Nasal Spray Products by Total Prescriptions (in thousands) for 2007 and 2008 (includes corresponding Graph/Chart).....II-61$350
   Table 4: US Allergy Drugs Market - Percentage Share Breakdown of Allergy Nasal Spray Products by Value Sales for 2007 and 2008 (includes corresponding Graph/Chart).....II-71$350
   Allergy: Definition.....II-8
Causes/ Factors.....II-8
Symptoms/ Triggers.....II-8
1$105
   Allergic Rhinitis – A Common Allergy.....II-9
Types of Allergic Rhinitis.....II-9
Diagnosis of Allergic Rhinitis.....II-9
Treatment of Allergy.....II-9
1$105
   Antihistamines.....II-10
Antihistamines - List of Select Generic Formulations and Products.....II-10
1$105
   Risks/ Side Effects.....II-11
Decongestants.....II-11
Decongestants - List of Select Generic Formulations and Products.....II-11
1$105
   Decongestant + Antihistamine - List of Select Generic Formulations and
  Products.....II-12
Risks/ Side Effects.....II-12
Corticosteroids.....II-12
1$105
   Intranasal Corticosteroids - List of Select Generic Formulations and
  Products.....II-13
Side Effects.....II-13
Allergy Shots.....II-13
Other Medicines.....II-13
Sodium Cromoglycate.....II-13
1$105
   Cromolyn Sodium.....II-14
Leukotriene Modifiers.....II-14
Glucocorticoids.....II-14
Leading Allergy Drugs.....II-14
Claritin.....II-14
Zyrtec.....II-14
1$105
   Benadryl.....II-15
Pollinex® Quattro.....II-15
Cortaid.....II-15
Visine-A.....II-15
Ocean Sinus Irrigation.....II-15
Crolom Eye Drops.....II-15
1$105
   McNeil Consumer Healthcare Launches Zyrtec for Children.....II-16
Cobalis Announces Online Launch of Anti-allergy Product.....II-16
Collegium Pharmaceutical Obtains FDA Approval for AllerNaze.....II-16
1$105
   Sanofi-aventis and UCB Win NDA Approval for Xyzal Oral Solution.....II-17
Sepracor Launches Omnaris Nasal Spray for Seasonal and Perennial Allergies.....II-17
1$105
   Sanofi Aventis Launches Allegra Orally Disintegrating Tablets.....II-18
Ranbaxy Wins FDA Approval for Generic Zyrtec.....II-18
Wockhardt Introduces Generic Cetirizine Tablets.....II-18
Hi-Tech Pharmacal Receives FDA Approval for Fluticasone Propionate.....II-18
Boca Pharmacal Wins FDA Approval for Palgic’s Generic Product.....II-18
1$105
   Ranbaxy Receives FDA Approval for Cetirizine Hydrochloride Oral Solution.....II-19
Perrigo and Teva Receive FDA Approval for Zyrtec-D.....II-19
Sanofi-aventis Receives FDA Approval for Nasacort AQ® Nasal Spray.....II-19
Sanofi-aventis and UCB Introduce Xyzal Anti-allergy Medication.....II-19
Sanofi-aventis Wins FDA Approval for Allegra® Oral Suspension.....II-19
1$105
   Matrixx Launches Zicam Multi-Symptom Cold & Flu Relief Products.....II-20
Ranbaxy Receives Approval to Market Claritin Reditabs’ Generic.....II-20
Procter & Gamble Introduces Nyquil D.....II-20
Leiner to Launch Naproxen Cold & Sinus Private Label Allergy Products.....II-20
1$105
   Merck Announces Business Merger Plan with Schering-Plough.....II-21
Hi-Tech Pharmacal to Acquire ECR Pharmaceuticals.....II-21
IBT Laboratories and ViraCor Announce Merger Plan.....II-21
1$105
   Lupin Acquires Rights to Collegium’s Intra-nasal Steroid.....II-22
Cobalis and Melodic Sign Agreement for PreHistin.....II-22
Patheon Receives Contract to Commercialize Allergy Drugs.....II-22
1$105
   Boehringer Ingelheim Signs Agreement for Actimis Acquisition.....II-23
Perrigo Acquires US Rights to Levocetirizine Tablets.....II-23
Sciele Pharma Acquires Verus Pharmaceuticals’ Allergy Injection.....II-23
1$105
   Sanofi-Aventis and Johns Hopkins University Division Sign Agreement.....II-24
Pipex Announces Effective Pharmaceuticals Acquisition.....II-24
Meda to Take Over American Company, MedPointe.....II-24
Private Group Proposes to Acquire Majority Interest in Inyx.....II-24
1$105
   Collegium Pharmaceutical, Inc......II-25
McNeil Consumer Healthcare.....II-25
Meda Pharmaceuticals, Inc......II-25
Novartis Consumer Healthcare, Inc......II-25
1$105
   Schering-Plough Corp......II-26
Sepracor, Inc......II-26
1$105
   Vicks.....II-271$105
   Table 5: US Recent Past, Current & Future Analysis for Allergy Drugs by Product Segment - Prescription Antihistamines, Prescription Corticosteroids, and OTC Allergy Drugs Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2007 through 2015 (includes corresponding Graph/Chart).....II-281$350
   Table 6: US Historic Review for Allergy Drugs by Product Segment - Prescription Antihistamines, Prescription Corticosteroid, and OTC Allergy Drugs Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2001 through 2006 (includes corresponding Graph/Chart).....II-291$350
   Table 7: US 15-Year Perspective for Allergy Drugs by Product Segment - Percentage Breakdown of Annual Value Sales for Prescription Antihistamines, Prescription Corticosteroids, and OTC Allergy Drugs Markets for Years 2003, 2009 & 2015 (includes corresponding Graph/Chart).....II-301$350
   Allergy – Overview.....III-1
Strategic Corporate Developments.....III-1
2$210
   Allergy – Overview.....III-3
Product Approvals.....III-3
1$105
   Allergy - Prevalence.....III-4
United Kingdom.....III-4
Allergy – Overview.....III-4
Russia.....III-4
Allergy – Overview.....III-4
Product Launch.....III-4
1$105
   Strategic Corporate Developments.....III-5
Select Players.....III-5
3$175
   Allergy – Overview.....III-8
Australia and New Zealand.....III-8
China.....III-8
Market Overview.....III-8
1$105
   OTC Medications – A Small, But Growing Market.....III-9
Market Analytics.....III-9
Table 8: Chinese Recent Past, Current & Future Analysis for Allergy Drugs - Annual Sales Figures in US$ Million for Years 2006 through 2015 (includes corresponding Graph/Chart).....III-9
1$200
   India.....III-10
Market Overview.....III-10
Malaysia.....III-10
Allergy – Overview.....III-10
1$105
  
Total Companies Profiled: 109 (including Divisions/Subsidiaries - 139)

Region/Country Players

The United States 26 Canada 2 Japan 8 Europe 40 France 4 Germany 7 The United Kingdom 4 Italy 4 Spain 4 Rest of Europe 17 Asia-Pacific (Excluding Japan) 49 Middle-east 13 Africa 1
Click here to request a full table of contents and more details on this project.